Page 1

Johnson & Johnson NEWS RELEASE Johnson & Johnson reports Q3 2026 results , raises 2026 guidance 2026-10-13 • 2026 Third - Quarter reported sales growth of 5.9 % to $ 25.4 Billion with operational growth of 6.0 % * and adjusted operational growth of 6.1 % * • 2026 Third - Quarter earnings per share ( EPS ) of $ 0.09 reflects a one - time special charge for the proposed talc litigation resolution , the acquisition of Firefly Bio , Inc. , and the strategic collaboration with Sail Biomedicines ; adjusted EPS * of $ 2.59 also reflects the impact of these M & A deals • Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $ 101.2 Billion or 7.4 % at the midpoint and increasing adjusted EPS * guidance by $ 0.06 to $ 11.10 or 2.9 % at the midpoint • Significant innovation including the market authorization of OTTAVA as the world's first table - integrated soft tissue robotic system , approval of IMAAVY in warm autoimmune hemolytic anemia ( wAIHA ) , and priority review for RYBREVANT FASPRO for advanced head and neck cancer NEW BRUNSWICK , N.J .-- ( BUSINESS WIRE ) -- Johnson & Johnson ( NYSE : JNJ ) today announced results for third - quarter 2026 . " Johnson & Johnson's strong third - quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio , " said Joaquin Duato , Chairman and Chief Executive Officer . " In the third quarter , we advanced breakthroughs that will redefine care for patients , from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma . This progress , together with strategic investments in high - growth areas , gives us clearer line of sight to double - digit growth by the end of the decade . " Overall financial results 1